Department of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Med Oncol. 2014 Mar;31(3):845. doi: 10.1007/s12032-014-0845-3. Epub 2014 Jan 28.
This study mainly focused on the impact of Hepatitis B virus (HBV) infection on the prognosis of diffuse large B cell lymphoma (DLBCL) patients in rituximab era, using a Cox regression model to ascertain the prediction value of the serum HBV marker in survivals. Three hundred and eighty four DLBCL patients treated with rituximab, cyclophosphamide, doxorubicin/epirubicin, vincristine and prednisone (R-CHOP-like regimens) or CHOP-like regimens were included. Progression-free survival (PFS) and overall survival (OS) of the patients have or have not received rituximab were analyzed separately. In the CHOP group, HBV infection has not been found a profound impact on the survivals. In the R-CHOP group, PFS and OS were inferior in HBsAg-positive patients (p=0.031 and p=0.006, respectively); after adjusting for International Prognostic Index parameters, HBsAg is an independent unfavorable factor for both PFS (RR=2.492) and OS (RR=2.589).
本研究主要关注乙型肝炎病毒（HBV）感染对利妥昔单抗时代弥漫性大 B 细胞淋巴瘤（DLBCL）患者预后的影响，采用 Cox 回归模型确定血清 HBV 标志物在生存中的预测价值。共纳入 384 例接受利妥昔单抗、环磷酰胺、多柔比星/表柔比星、长春新碱和泼尼松（R-CHOP 样方案）或 CHOP 样方案治疗的 DLBCL 患者。分别分析了接受和未接受利妥昔单抗治疗的患者的无进展生存（PFS）和总生存（OS）。在 CHOP 组中，HBV 感染未发现对生存有显著影响。在 R-CHOP 组中，HBsAg 阳性患者的 PFS 和 OS 较差（p=0.031 和 p=0.006）；调整国际预后指数参数后，HBsAg 是 PFS（RR=2.492）和 OS（RR=2.589）的独立不良因素。
